Are all first-generation antipsychotics equally effective in treating schizophrenia?
As most of the single meta-analytic comparisons can be regarded as underpowered, the evidence for the assumption of comparable efficacy of all FGAs is inconclusive. We therefore cannot confirm or reject the statements of previous narrative, unsystematic reviews in this regard. Our findings were limited by the small sample size in the individual comparisons and the low methodological quality in many included studies.
Therapeutic and significantly supratherapeutic exposure to linagliptin is not associated with QT interval prolongation.